ANSM review of PathoQuest’s NGS-based trancriptome assay
The Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) reviewed PathoQuest’s NGS-based transcriptome assay for detecting adventitious agents.
pathoquest.comCrawled Nov 1, 2026
The Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) reviewed PathoQuest’s NGS-based transcriptome assay for detecting adventitious agents.
The PathoQuest mission is to develop proprietary, rapid turn-around-time GMP Next Generation Sequencing (NGS) assays and bioinformatic approaches
PathoQuest offers GMP-compliant, validated NGS-based testing for biotesting and characterization through its iDTECT platform.
PathoQuest’s assay workflow, from sample preparation to bioinformatics, is validated to Good Manufacturing Practice (GMP).
PathoQuest’s iDTECT NGS-based assays meet regulatory standards for biotesting accuracy and compliance.
PathoQuest announces its Next-Gen Biosafety Masterclass, an in-person event dedicated to “Next Generation Sequencing (NGS) in Biosafety Testing: From Regulation to Routine Use.”
PathoQuest announces the publication of the results of a seminal study in Vaccine. This unique study demonstrated that the Company's proprietary, good manufacturing practice (GMP) grade NGS-based assay had a greater capability of detecting viral contaminants when compared to in vivo assays.
𝐍𝐄𝐖 𝐏𝐔𝐁𝐋𝐈𝐂𝐀𝐓𝐈𝐎𝐍: A comparative study conducted by members of the 𝐀𝐕𝐃𝐓𝐖𝐆, and the FDA, has been published in npj Vaccines.
PathoQuest partners with Amazon Web Services to implement a GMP compliant, cloud-based computing and data storage platform
Dr. Guillaume Deplaine has 10 years of experience in the Biotechnology industry. Prior to joining PathoQuest, Dr. Deplaine was the Quality Control and Analytical Development Head at CELLforCURE a CDMO specialized in CART Cells manufacturing, and was part of the Novartis Group.
PathoQuest partners with Amazon Web Services to implement a cloud-based computing and data storage platform.
PathoQuest, a provider of Next Generation Sequencing (NGS)–based biosafety testing, agreed to be acquired by Charles River Laboratories, a supplier of biopharmaceutical research products and services.
Paris, France
PathoQuest, a spin-off of the Institut Pasteur, offers quality control solutions for pharmaceutical testing.
PathoQuest develops quality testing methods to help customers deliver biotherapies to patients.
PathoQuest CEO Jean-François Brepson discusses NGS innovation, the shift from animal testing, and the future of biologics.
PathoQuest appointed Stanley Prince as chief commercial officer.
The 3Rs model to ensure the ethical treatment of animals has seen a significant move away from both direct and indirect animal testing models.
PathoQuest’s digital Quality Management System (QMS) and Document Management System (DMS) support laboratory procedures, reports, and certificates.
PathoQuest drives innovation in quality testing to deliver new biotherapies rapidly and safely to patients.
PathoQuest provides NGS-based biosafety assays for biologics quality testing in biopharmaceuticals.